File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

TitleDoxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial
Authors
Issue Date1988
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 1988, v. 62 n. 3, p. 479-483 How to Cite?
AbstractTo assess the efficacy and safety of Adriamycin (Adria Laboratories, Columbus, OH) in inoperable hepatocelluar carcinoma (HCC), 60 patients were randomized to receive Adriamycin 60 to 75 mg/m2 at 3-week intervals and 46 patients to receive no antitumor therapy. The median survival rate of the Adriamycin group was 10.6 weeks; that of the group receiving no antitumor therapy was 7.5 weeks (P = 0.036). Adriamycin induced tumor regression of 25% to 50% in 5% of patients and of over 50% in only 3.3% of patients. It caused fatal complications (septicemia and cardiotoxicity) in 25% of patients. The severity of neutropenia leading to septicemia for a particular dose was unpredictable. Four of eight patients who developed cardiotoxicity received les than 500 mg/m2 of Adriamycin. We conclude that Adriamycin is not an ideal drug for the treatment of inoperable HCC.
Persistent Identifierhttp://hdl.handle.net/10722/161750
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorChan, GCBen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLin, HJen_US
dc.date.accessioned2012-09-05T05:14:39Z-
dc.date.available2012-09-05T05:14:39Z-
dc.date.issued1988en_US
dc.identifier.citationCancer, 1988, v. 62 n. 3, p. 479-483en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/161750-
dc.description.abstractTo assess the efficacy and safety of Adriamycin (Adria Laboratories, Columbus, OH) in inoperable hepatocelluar carcinoma (HCC), 60 patients were randomized to receive Adriamycin 60 to 75 mg/m2 at 3-week intervals and 46 patients to receive no antitumor therapy. The median survival rate of the Adriamycin group was 10.6 weeks; that of the group receiving no antitumor therapy was 7.5 weeks (P = 0.036). Adriamycin induced tumor regression of 25% to 50% in 5% of patients and of over 50% in only 3.3% of patients. It caused fatal complications (septicemia and cardiotoxicity) in 25% of patients. The severity of neutropenia leading to septicemia for a particular dose was unpredictable. Four of eight patients who developed cardiotoxicity received les than 500 mg/m2 of Adriamycin. We conclude that Adriamycin is not an ideal drug for the treatment of inoperable HCC.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_US
dc.relation.ispartofCanceren_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma, Hepatocellular - Drug Therapyen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDoxorubicin - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver Neoplasms - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRandom Allocationen_US
dc.titleDoxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trialen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L-
dc.identifier.pmid2839280-
dc.identifier.scopuseid_2-s2.0-0023765990en_US
dc.identifier.volume62en_US
dc.identifier.issue3en_US
dc.identifier.spage479en_US
dc.identifier.epage483en_US
dc.identifier.isiWOS:A1988P330000005-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridChan, GCB=37044632700en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats